The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations
Abstract
PURPOSE: Recent laboratory data suggest a role for BRCA1/2 in the cellular response to DNA damage. There is a paucity of clinical data, however, examining the effect of radiotherapy (RT), which causes double-strand breaks, on breast tissue from BRCA1/2 mutation carriers. Thus the goals of this study were to compare rates of radiation-associated complications, in-breast tumor recurrence, and distant relapse in women with BRCA1/2 mutations treated with breast-conserving therapy (BCT) using RT with rates observed in sporadic disease. PATIENTS AND METHODS: Seventy-one women with a BRCA1/2 mutation and stage I or II breast cancer treated with BCT were matched 1:3 with 213 women with sporadic breast cancer. Conditional logistic regression models were used to compare matched cohorts for rates of complications and recurrence. RESULTS: Tumors from women in the genetic cohort were associated with high histologic (P = .0004) and nuclear (P = .009) grade and negative estrogen (P = .0001) and progesterone (P = .002) receptors compared with tumors from the sporadic cohort. Using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity scoring, there were no significant differences in acute or chronic morbidity in skin, subcutaneous tissue, lung, or bone. The 5-year actuarial overall survival, relapse-free survival, and rates of tumor control in the treated breast for the patients in the genetic cohort were 86%, 78%, and 98%, respectively, compared with 91%, 80%, and 96%, respectively, for the sporadic cohort (P = not significant). CONCLUSION: There was no evidence of increased radiation sensitivity or sequelae in breast tissue heterozygous for a BRCA1/2 germline mutation compared with controls, and rates of tumor control in the breast and survival were comparable between BRCA1/2 carriers and controls at 5 years. Although additional follow-up is needed, these data may help in discussing treatment options in the management of early-stage hereditary breast cancer and should provide reassurance regarding the safety of administering RT to carriers of a germline BRCA1/2 mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Self-citationFisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Self-citationLinkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Fisher, B., Bauer, M., Margolese, R., Poisson, R., Pilch, Y., Redmond, C., Fisher, E., Wolmark, N., Deutsch, M., Montague, E., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121101 · Cited by 2,194
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D.-S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., & Bradley, A. (1997) · Nature · doi:10.1038/386804a0 · Cited by 1,072
Jacobson, J. A., Danforth, D. N., Cowan, K. H., d'Angelo, T., Steinberg, S. M., Pierce, L., Lippman, M. E., Lichter, A. S., Glatstein, E., & Okunieff, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321402 · Cited by 892
Self-citationThe genetic attributable risk of breast and ovarian cancer
Claus, E. B., Schildkraut, J. M., Thompson, W. D., & Risch, N. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2318::aid-cncr21>3.0.co;2-z · Cited by 744
BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., Jablon, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362002 · Cited by 685
Self-citationBreast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Self-citationArriagada, R., Lê, M. G., Rochard, F., & Contesso, G. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1558 · Cited by 612
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Pierce, S. M., Recht, A., Lingos, T. I., Abner, A., Vicini, F., Silver, B., Herzog, A., & Harris, J. R. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90895-o · Cited by 482
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., & Lynch, H. T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w · Cited by 454
Self-citationSurvival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Cancer in the Contralateral Breast after Radiotherapy for Breast Cancer
Boice, J. D., Harvey, E. B., Blettner, M., Stovall, M., & Flannery, J. T. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261201 · Cited by 432
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
Tonin, P., Weber, B., Offit, K., Couch, F., Rebbeck, T. R., Neuhausen, S., Godwin, A. K., Daly, M., Wagner-Costalos, J., Berman, D., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1179 · Cited by 313
Self-citationRapid detection of BRCA1 mutations by the protein truncation test
Hogervorst, F. B. L., Cornelis, R. S., Bout, M., Vliet, M. V., Oosterwijk, J. C., Olmer, R., Bakker, B., Klijn, J. G. M., Vasen, H. F. A., Meijers-Heijboer, H., et al. (1995) · Nature Genetics · doi:10.1038/ng0695-208 · Cited by 312
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
Recht, A., Silen, W., Schnitt, S. J., Connolly, J. L., Gelman, R. S., Rose, M. A., Silver, B., & Harris, J. R. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)90002-5 · Cited by 220
BRCA1 and BRCA2: from molecular genetics to clinical medicine.
Blackwood, M. A., & Weber, B. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1969 · Cited by 179
Self-citationBernstein, J. L., Thompson, W. D., Risch, N., & Holford, T. R. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116565 · Cited by 160
Robson, M., Levin, D., Federici, M., Satagopan, J., Bogolminy, F., Heerdt, A., Borgen, P., McCormick, B., Hudis, C., Norton, L., et al. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2112 · Cited by 158
Adjuvant Radiotherapy and Risk of Contralateral Breast Cancer
Storm, H. H., Andersson, M., Boice, J. D., Blettner, M., Stovall, M. A., Mouridsen, H. T., Dombernowsky, P., Rose, C., Jacobsen, A.-B., & Pedersen, M. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1245 · Cited by 134
Hankey, B. F., Curtis, R. E., Naughton, M. D., Boice, J. D., & Flannery, J. (1983) · PubMed · Cited by 132
Turner, B. C., Harrold, E., Matloff, E., Smith, T., GUMBS, A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P., Thomas, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3017 · Cited by 118
Self-citationResponse to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
Gaffney, D. K., Brohet, R. M., Lewis, C. M., Holden, J. A., Buys, S. S., Neuhausen, S. L., Steele, L., Avizonis, V. N., Stewart, J. R., & Cannon‐Albright, L. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(98)00023-1 · Cited by 109
Self-citationChabner, E., Nixon, A., Gelman, R., Hetelekidis, S., Recht, A., Bornstein, B., Connolly, J., Schnitt, S., Silver, B., Manola, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2045 · Cited by 78
Self-citationJewish religion and risk of breast cancer
Egan, K. M., Trichopoulos, D., Stampfer, M. J., Willett, W. C., Newcomb, P. A., Trentham‐Dietz, A., Longnecker, M. P., Baron, J. A., Stampfer, M. J., & Willett, W. C. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91485-3 · Cited by 68
Pierce, L. J., Strawderman, M., Douglas, K. R., & Lichter, A. S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00464-1 · Cited by 43
Self-citationSignificance of Family History in Breast Cancer Treated with Breast Conservation Therapy
Chen, L. M., Mundt, A. J., Powers, C., Halpern, H. J., & Weichselbaum, R. R. (1996) · The Breast Journal · doi:10.1111/j.1524-4741.1996.tb00104.x · Cited by 12
Hellmän, S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3007 · Cited by 11
Research works printed but not linked: 8
- 10.1016/0360-3016(91)90782-Y · doi:10.1016/0360-3016(91)90782-y
- 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y · doi:10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y
- 10.1111/j.1524-4741.1995.tb00241.x · doi:10.1111/j.1524-4741.1995.tb00241.x
- 10.1016/0360-3016(91)90773-W · doi:10.1016/0360-3016(91)90773-w
- 10.1038/bjc.1985.196 · doi:10.1038/bjc.1985.196
- 10.1007/BF00348194 · doi:10.1007/bf00348194
- 10.1016/0360-3016(85)90179-8 · doi:10.1016/0360-3016(85)90179-8
- 10.1016/S0360-3016(99)00132-7 · doi:10.1016/s0360-3016(99)00132-7
Cited by
Bentzen, S. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1950 · Cited by 1,096
American Cancer Society Guidelines for Breast Cancer Screening: Update 2003
Smith, R. A., Saslow, D., Andrews Sawyer, K., Burke, W., Costanza, M. E., Evans, W. P., Foster, R. S., Hendrick, E., Eyre, H. J., & Sener, S. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.3.141 · Cited by 770
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationPierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Self-citationTung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Self-citation
Metadata
- Authors
- Pierce, L. J., Strawderman, M., Narod, S. A., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L. J., Nixon, A., Garber, J., Berg, C., Isaacs, C., Heimann, R., Olopade, O. I., Haffty, B., & Weber, B. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-10-19
- Volume
- 18
- Issue
- 19
- Pages
- 3360-3369
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1828494712
- Cited by
- 268
- References
- 38
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.